75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)(Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, NON-CONTROLLING INTEREST AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) link:presentationLink link:calculationLink link:definitionLink 75070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, NON-CONTROLLING INTEREST AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75080 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Nature of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Warrant Liability link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Related-party Transactions link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Variable Interest Entities link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Warrant Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Convertible Preferred Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Amortized Cost and Fair Value of Company's Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Marketable Securities Gross Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Maturity Information Based on Fair Value of Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Carried at Fair Value on Recurring Basis by Level, within Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Fair Value Measurements - Roll-forward of Aggregate Fair Values of Liabilities Determined by Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Collaboration Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Collaboration Agreements - Additional Information (Details) 1 link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Collaboration Agreements - Additional Information (Details) 1 [Default] link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Property and Equipment - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Warrant Liability - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Warrant Liability - Schedule of Assumptions Used to Determine the Fair Value of the Warrant (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Convertible Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Convertible Preferred Stock - Summary of Convertible Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Common Stock - Summary of Total Shares of Common Stock Reserved for Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Stock-based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Stock-based Compensation - Schedule of Grant-date Fair Value of Options Granted to Employees, Non-Employees and Directors (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Stock-based Compensation - Summary of of Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Related-party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Variable Interest Entities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Segment Information - Schedule of Significant Expense Categories and Amounts Align with Segment-Level Information (Details) link:presentationLink link:calculationLink link:definitionLink Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Unit, Forfeited and Expired (in dollars per share) Cash Equivalents And Marketable Securities [Abstract] Cash equivalents and marketable securities. Available-for-sale Securities Classified by Contractual Maturity Date [Table Text Block] Available-for-sale securities classified by contractual maturity date. Summary of Maturity Information Based on Fair Value of Available-for-sale Securities Entity Incorporation, State or Country Code Preferred Stock, Shares Issued Preferred stock, shares issued Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Liabilities Beginning balance Ending balance Accounts payable Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable, Total Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Maturing in one year or less Plan Name [Axis] Equity [Abstract] Entity Current Reporting Status Computers And Software [Member] Computers and software. Computers and Software US Government Agencies Debt Securities [Member] Government securities [Member] Operating Expenses [Abstract] Operating expenses: Fair Value, Inputs, Level 2 [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price per Unit Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Shares Authorized Common stock share authorized Common stock authorized Document Fiscal Period Focus Entity Shell Company Remaining Fixed Transaction Price Remaining fixed transaction price. Remaining fixed transaction price Beginning balance (in shares) Temporary Equity, Shares Outstanding Ending balance (in shares) Convertible Preferred Stock Outstanding Convertible preferred stock outstanding Cash and Cash Equivalent Cash and Cash Equivalent, Total Cash equivalents Cash and cash equivalents, end of period Cash and cash equivalents Finance Lease Right Of Use Assets [Member] Finance lease right of use assets. Finance Lease Right of Use Assets Common Stock, Shares, Issued Common stock shares issued Asset Class [Domain] Statement [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value Percentage of research and development costs commitments Percentage of Research and Development Costs Commitments Percentage of research and development costs commitments. Statement [Line Items] Entity Filer Category Variable Interest Entity Disclosure [Text Block] Variable Interest Entities Series C Convertible Preferred Stock [Member] Series C Convertible Preferred Stock. Series C Convertible Preferred Stock Liabilities and Equity Total liabilities, convertible preferred stock, non-controlling interests and stockholders' equity (deficit) Payments to Acquire Marketable Securities Purchase of marketable securities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price Per Unit exercisable (in dollars per share) Long-Lived Tangible Asset [Axis] Fifth Target Program [Member] Fifth Target Program. Fifth Target Program Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Nature of Business and Basis of Presentation [Table] Nature Of Business And Basis Of Presentation [Table] Nature of Business and Basis of Presentation [Table]. Stock Options Interest income Investment Income, Interest Interest income Reclassification Of Warrant Liability To Equity Reclassification of warrant liability to equity. Reclassification of warrant liability to equity Variable Interest Entity [Table] Additional Paid in Capital, Common Stock Additional paid-in capital Related Party [Member] Related Party Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Line Items] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Risk Free Interest Rate Securities Delinquent On Contractual Payments Securities delinquent on contractual payments. Securities delinquent on contractual payments Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Stock options issued subject to performance condition Number of Options, Granted (in shares) Earnings Per Share, Basic Earnings Per Share, Basic, Total Net loss per share, basic Cellarity [Member] Cellarity member. Cellarity Transaction price Transaction price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Stock options remains outstanding Number of Options, Outstanding balance (in shares) Number of Options, Outstanding balance (in shares) Variable Interest Entity [Line Items] Liabilities, Current Total current liabilities Increase (Decrease) in Accounts Receivable Accounts receivable Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Roll-forward of Aggregate Fair Values of Liabilities Determined by Level 3 Inputs Collaboration Agreement Commercial Milestones Collaboration agreement commercial milestones. Collaboration agreement commercial milestones Equity, Attributable to Parent [Abstract] Stockholders' equity (deficit): Shares Reserved For Future Issuance Under The 2026 Plan [Member] Shares reserved for future issuance under the 2026 plan member. Shares Reserved for Future Issuance Under the 2026 Plan Entity Small Business Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Liabilities, Total Accrued expenses and other liabilities Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Total Proceeds from Issuance Initial Public Offering Net proceeds from issuance initial public offering Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses Sixth Target Program [Member] Sixth Target Program. Sixth Target Program Stock Options Outstanding [Member] Stock options outstanding member. Stock Options Outstanding Warrants and Rights Outstanding, Measurement Input Warrants and rights outstanding, measurement input Share-Based Payment Arrangement [Text Block] Stock-based Compensation Collaborative Arrangements [Abstract] Collaborative Arrangements. Amendment Flag Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrant issued, shares Liabilities and Equity [Abstract] Liabilities, convertible preferred stock, non-controlling interest and stockholders' deficit Entity Address, Postal Zip Code Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Increase (Decrease) in Operating Lease Liability Operating lease liabilities Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Common Stock [Member] Common Stock Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Unit, Granted (in dollars per share) Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Debt Securities, Available-for-Sale [Line Items] Entity Address, Address Line One Schedule of grant-date fair value of options granted to employees, non-employees and directors Schedule of Grant-date Fair Value of Options Granted to Employees, Non-Employees and Directors Fair Value Hierarchy and NAV [Axis] Earnings Per Share [Abstract] Temporary Equity, Carrying Amount, Attributable to Parent Convertible preferred stock Ending balance Beginning balance Carrying Value Supplemental Cash Flow Information [Abstract] Supplemental disclosure of noncash investing and financing information: Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to non-controlling interests Net loss allocated to non-controlling interest Net loss attributable to non-controlling interests Document Type Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Agreement With the University of Texas M.d. Anderson Cancer Center [Member] Agreement with The University of Texas M.D. Anderson Cancer Center. MD Anderson Equity Incentive Plan 2019 [Member] Equity Incentive Plan 2019 2019 Equity Incentive Plan Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Entity Central Index Key Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Fair Value Adjustment of Warrants Change in fair value of convertible preferred stock warrant liability Changes in fair value of convertible preferred stock warrant liability Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of diluted net loss per share Common Stock, Par or Stated Value Per Share Common stock, par value Non-Cash Lease Expense Non-cash lease expense. Non-cash lease expense Noncontrolling Interest, Increase from Subsidiary Equity Issuance Contributions from non-controlling interests Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Life (in Years), Outstanding balance Debt Securities, Available-for-Sale, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Total Amortized Cost Basis Estimated Fair Value Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale, Total Schedule of Stockholders Equity [Table Text Block] Summary of Total Shares of Common Stock Reserved for Issuance Parent [Member] Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of Options, Exercised (in shares) Number of Options, Exercised (in shares) Current Fiscal Year End Date Restricted Cash and Cash Equivalent, Noncurrent Restricted Cash and Cash Equivalent, Noncurrent, Total Long-term restricted cash Document Quarterly Report Entity Address, State or Province Amortization and accretion on marketable securities Investment Income, Net, Amortization of Discount and Premium Investment Income, Net, Amortization of Discount and Premium, Total Warrant to purchase convertible preferred stock Warrant to Purchase Convertible Preferred Stock Warrant to purchase convertible preferred stock. Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of convertible preferred stock into common stock upon initial public offering Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss attributable to Generate Biomedicines, Inc. stockholders Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance Shares reserved for exercise stock options Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Variable interest entity, ownership percentage Marketable Securities, Current Marketable securities Equity, Attributable to Noncontrolling Interest Equity, Attributable to Noncontrolling Interest, Ending Balance Equity, Attributable to Noncontrolling Interest, Beginning Balance Equity, Attributable to Noncontrolling Interest, Total Non-controlling interest Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Collaborative Arrangement Disclosure [Text Block] Collaboration Agreements Proceeds from Sale and Maturity of Marketable Securities Proceeds from sales and maturities of marketable securities Warrant To Purchase Convertible Preferred Stock [Member] Warrant to purchase convertible preferred stock. Warrant to Purchase Convertible Preferred Stock Warrant to purchase convertible preferred stock [Member] Share Based Payment Performance Condition Specified Payment Received Share based payment performance condition specified payment received. Stock options Issued specified payments Deferred Revenue, Current Deferred Revenue, Current, Total Deferred revenue - current Property, Plant and Equipment [Abstract] Other Assets, Noncurrent Other assets Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Input, Expected Term [Member] Measurement Input, Expected Term Proceeds from issuance of convertible preferred stock, net of issuance costs Proceeds from Issuance of Convertible Preferred Stock Antidilutive Securities [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Stock options shares expired Related Party Transaction [Axis] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive (Loss) Income [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Cash and Cash Equivalents [Domain] Minimum [Member] Minimum Financial Instrument [Axis] Assets, Current [Abstract] Current assets: Series B Convertible Preferred Stock Outstanding [Member] Series b convertible preferred stock outstanding member. Series B Convertible Preferred Stock Outstanding Warrant to purchase stock upon conversion Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Marketable Securities Gross Unrealized Losses [Table Text Block] Marketable securities gross unrealized losses Summary of Marketable Securities Gross Unrealized Losses Fair Value, Inputs, Level 3 [Member] Segment Reporting [Abstract] Business Combination, Recognized Asset Acquired, Asset Business Combination, Recognized Asset Acquired, Asset, Total Net assets acquired Schedule of Assets and Liabilities Carried at Fair Value on Recurring Basis by Level, within Fair Value Hierarchy Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Liabilities, Current [Abstract] Current liabilities: Related Party Transactions [Abstract] Restricted Cash and Cash Equivalent Restricted Cash and Cash Equivalent, Total Restricted cash and cash equivalents (VIE) Commitments and Contingencies Commitments and contingencies (Note 15) General and Administrative Expense [Member] General and Administrative Reverse split of shares of common stock Stockholders' Equity, Reverse Stock Split Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Current portion of finance lease liabilities Finance Lease, Liability, Current Non-current liabilities: Liabilities, Noncurrent [Abstract] Capital Expenditures Incurred but Not yet Paid Purchase of property and equipment included in the accounts payable and accrued liabilities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net loss Net loss Consolidated net loss Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted average common shares outstanding, basic Agreement With Roswell Park Comprehensive Cancer Center [Member] Agreement with Roswell Park Comprehensive Cancer Center. Roswell Park Scenario [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value Options exercisable Segment Reporting, Expense Information Used by CODM, Description Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Long-Lived Tangible Asset [Domain] Subsequent Events [Text Block] Subsequent Events Related Party Transactions Disclosure [Text Block] Related-party Transactions APIC, Share-Based Payment Arrangement, Increase for Cost Recognition APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation Equity, Attributable to Parent Total stockholders' equity (deficit) Beginning balance Ending Balance Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Statement of Stockholders' Equity [Abstract] Third Target Program Third Target Program [Member] Third Target Program. Nature Of Business And Basis Of Presentation [Abstract] Nature Of Business And Basis Of Presentation [Abstract]. Nature of Business and Basis of Presentation [Abstract] Cash Equivalents Cash Equivalents [Member] Use of Estimates, Policy [Policy Text Block] Use of Estimates Prior PMCo Agreement Collaborative Arrangement [Member] Leasehold Improvements [Member] Leasehold Improvements Gain (Loss), Foreign Currency Transaction, before Tax Gain (Loss), Foreign Currency Transaction, before Tax, Total Foreign currency exchange loss Temporary Equity [Text Block] Temporary equity. Convertible Preferred Stock Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS Investment in equity Investment in equity Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Summary of of Share-based Compensation Expense Depreciation expense Depreciation, Nonproduction Warrants and Rights Note Disclosure [Abstract] Non-Controlling Interest [Member] Noncontrolling Interest [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses and Other Current Liabilities Amgen Collaboration Agreement [Member] Amgen Collaboration Agreement. Amgen Collaboration Agreement Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Segment Reporting, Other Segment Item, Amount Other segment expenses Plan Name [Domain] Other assets Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets, Total Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Business Description and Basis of Presentation [Text Block] Nature of Business and Basis of Presentation Related and Nonrelated Parties [Axis] Class of Warrant or Right [Table] Government Securities [Member] Government securities. Government Securities Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Fair value measurement liability, transfers into Level 3 Entity Address, City or Town Sean Martin Sean Martin [Member] Sean Martin. Security Exchange Name Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Total property and equipment Summary of Convertible Preferred Stock Temporary Equity [Table Text Block] Cumulative adjustment to revenue Cumulative Adjustment to Revenue Cumulative adjustment to revenue. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before provision for income taxes Outstanding number of share increased annually Outstanding number of share increased annually Percentage of outstanding number of share increased annually Measurement Input Type [Domain] Antidilutive Securities, Name [Domain] Marketable Securities Matured Duration Marketable securities matured duration. Marketable securities matured duration Temporary Equity, Dividends, Adjustment Convertible preferred stock accrued dividends Convertible preferred stock accrued dividends Statistical Measurement [Domain] 2019 and 2026 Equity Incentive Plan Equity Incentive Plan 2019 And 2026 [Member] Equity Incentive Plan 2019 And 2026. Class of Warrant or Right, Exercise Price of Warrants or Rights Warrant exercise price Warrants and rights outstanding, per share Total current assets Assets, Current Stock-based compensation expense Share-Based Payment Arrangement, Expense Total stock-based compensation expense Stock-based compensation Document Period End Date General And Administrative Personnel-related (Excluding Stock-based Compensation) General and administrative personnel-related (excluding stock-based compensation). General and administrative personnel-related (excluding stock-based compensation) Collaboration Arrangements Upfront Payment Received Collaboration arrangements upfront payment received. Upfront payments received Fair Value Hierarchy and NAV [Domain] Novartis Collaboration Agreement Novartis Collaboration Agreement [Member] Novartis Collaboration Agreement. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number of Options, Options exercisable (in shares) Francis Arnold Francis Arnold [Member] Francis Arnold. Statement of Financial Position [Abstract] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Underwriting Discounts And Commissions And Offering Expenses Payable Underwriting discounts and commissions and offering expenses payable. Underwriting discounts and commissions and offering expenses payable Redeemable Convertible Preferred Stock [Member] Redeemable Convertible Preferred Stock Antidilutive Security, Excluded EPS Calculation [Table] Milestone Payment Recognized Milestone Payment Recognized. Milestone payment recognized Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Provision for credit losses on marketable securities Provision for Credit Losses on Marketable Securities Provision for credit losses on marketable securities. Fourth Target Program [Member] Fourth Target Program. Fourth Target Program Class of Stock [Axis] Warrants and Rights Outstanding, Maturity Date Warrants and rights outstanding expiring date Liabilities Total liabilities Financial Instruments [Domain] Deferred revenue Increase (Decrease) in Deferred Revenue Accrued Expenses and Other Liabilities Current Accrued expenses and other liabilities current. Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Collaboration agreement development and regulatory milestones Collaboration Agreement Development And Regulatory Milestones Collaboration agreement development and regulatory milestones. Cash and Cash Equivalent [Table] First Target Program [Member] First Target Program. First Target Program Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted average common shares outstanding, diluted Entity File Number Lab Equipment [Member] Lab equipment. Lab Equipment OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized loss on marketable securities Unrealized gain (loss) on marketable securities Cover [Abstract] Measurement Input Type [Axis] Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Fair value measurement liability, transfers out of Level 3 Fair Value Measurement Liabilities, Level 2 to Level 1 Transfers, Amount Fair value measurement liabilities, level 2 to level 1 transfers, amount. Fair value measurement liabilities, level 2 to level 1 transfers Scenario [Domain] Nature of Business and Basis of Presentation [Line items] Nature of Business and Basis of Presentation [Line items] Nature of Business and Basis of Presentation [Line items]. Number of Operating Segments Number of operating segments Sale of Stock [Domain] Segment Reporting Disclosure [Text Block] Segment Information General and Administrative Expense General and Administrative Expense, Total GeneralAndAdministrativeExpense General and administrative Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock. Series B Convertible Preferred Stock Temporary Equity, Liquidation Preference Liquidation Preference Vesting of stock options with performance condition Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares 2026 Equity Incentive Plan Equity Incentive Plan 2026 [Member] Equity Incentive Plan 2026 Number of Options, Forfeited/Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Conversion of convertible preferred stock into common stock upon initial public offering (in shares) Temporary Equity, Shares, Conversion of Convertible Securities Temporary equity, shares, conversion of convertible securities. Conversion of convertible preferred stock into common stock upon initial public offering (in shares) Shares reserved for exercise of outstanding Warrant [Member] Shares reserved for exercise of outstanding warrant member. Shares Reserved for Exercise of Outstanding Warrant Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Not Yet Adopted Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Conversion of convertible preferred stock into common stock upon initial public offering (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Convertible preferred stock converted into shares of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Restricted stock awards, and other stock-based award vesting period Business Combination, Recognized Liability Assumed, Liability Business Combination, Recognized Liability Assumed, Liability, Total Liabilities Flagship Pioneering [Member] Flagship pioneering member. Flagship Pioneering Depreciation Depreciation, Total Depreciation expense External research and development costs - GB-0895 Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Ending balance (in shares) Common Stock, Shares, Outstanding Beginning balance (in shares) Common stock shares outstanding Operating lease liabilities - current Operating Lease, Liability, Current Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Remaining transaction price Revenue, Remaining Performance Obligation, Amount Document Transition Report Operating Expenses Total operating expenses Operating expenses Term Deposits [Member] Term deposits. Term Deposits Term deposits [Member] Research and Development Expense Research and Development Expense, Total Research and development Research and development Research and development cost Fair Value Debt Securities, Held-to-Maturity, Fair Value Debt Securities, Held-to-Maturity, Fair Value, Total Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Convertible Preferred Stock Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss Statement of Cash Flows [Abstract] Series A Convertible Preferred Stock [Member] Series A convertible preferred stock. Series A Convertible Preferred Stock Stock Issued During Period, Value, New Issues Issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Common Stock Equity [Text Block] Earnings Per Share [Text Block] Net Loss Per Share Measurement Input, Expected Dividend Rate [Member] Measurement Input, Expected Dividend Rate Net loss Net loss attributable to Generate Biomedicines, Inc. stockholders Net loss attributable to Generate Biomedicines, Inc. stockholders Consolidated net loss attributable to Generate Biomedicines, Inc. stockholders Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value Outstanding balance Transaction Price Allocated to The Target Program Transaction price allocated to the target program. Transaction price allocated to the target program Warrants and Rights Outstanding, Term Warrant, original term Warrant outstanding, term Common Stock Issuable Upon Conversion Preferred Stock, Convertible, Shares Issuable Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Assets [Abstract] Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Construction in Progress [Member] Construction in Process Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Document Fiscal Year Focus Stock Option Grants Lapse And Forfeited Date Stock option grants lapse and forfeited date. Stock option grants lapse and forfeited date Warrant to Purchase Series a Convertible Preferred Stock [Member] Warrant to purchase series a convertible preferred stock. Warrant to Purchase Series A Convertible Preferred Stock Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total Change in fair value Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Remaining transaction price recognized period Investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Second Target Program [Member] Second Target Program. Second Target Program Accounts Payable, Current Accounts Payable, Current, Total Accounts payable Interest Expense, Nonoperating Interest Expense, Nonoperating, Total Interest expense Interest expense Research and Development Expense [Member] Research and Development Issuance of Series C convertible preferred stock (net of issuance costs of $28) (in shares) Temporary Equity Stock Issued During Period Shares New Issues Temporary equity stock issued during period shares new issues. Other Liabilities Other Liabilities, Total Amount owed to Flagship Other liabilities Proceeds from Stock Options Exercised Proceeds from exercise of stock options Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] Measurement Input, Share Price Measurement Input, Share Price [Member] Sale of Stock, Consideration Received on Transaction Amount received for stock sold in collaboration Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to Generate Biomedicines, Inc. common stockholders Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Unrecognized compensation expense Temporary Equity, Stock Issued During Period, Value, New Issues Issuance of Series C convertible preferred stock (net of issuance costs of $28) Sale of Stock [Axis] Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash (used in) provided by investing activities Title of 12(b) Security Money Market Funds [Member] Money Market Funds Related and Nonrelated Parties [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Temporary Equity, Shares Issued Convertible Preferred Stock Issued Convertible preferred stock issued Class of Warrant or Right [Line Items] Research and development personnel-related (excluding stock-based compensation) Research And Development Personnel-related (Excluding Stock-based Compensation) Research and development personnel-related (excluding stock-based compensation). Other long term liabilities Other Liabilities, Noncurrent Consolidated Entities [Axis] Maturing in one to five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Property, Plant and Equipment [Table Text Block] Summary of Property and Equipment Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price per Unit, Outstanding balance (in dollars per share) Weighted Average Exercise Price per Unit, Outstanding balance (in dollars per share) Fair Value, Recurring and Nonrecurring [Table] Accrued Liabilities and Other Liabilities [Abstract] Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Measurement Frequency [Domain] Statement of Income Location, Balance [Axis] Collaboration Agreement Development Milestones Collaboration agreement development milestones. Collaboration agreement development milestones Trading Symbol Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Related Party Transaction [Table] Employee-related Liabilities, Current Employee-related Liabilities, Current, Total Compensation and benefit Financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Fair Value, Recurring [Member] Entity Ex Transition Period Fair Value Measurement Inputs and Valuation Techniques [Line Items] Equity Components [Axis] Accounts payable Accounts Payable Accounts Payable, Total Nonoperating Income (Expense) Total other income (expense), net Equity Component [Domain] Conversion of convertible preferred stock into common stock upon initial public offering, Value Temporary Equity, Value, Conversion of Convertible Securities Temporary equity, value, conversion of convertible securities. Conversion of convertible preferred stock into common stock upon initial public offering Asset Class [Axis] Proceeds from Noncontrolling Interests Contributions from non-controlling interests Deferred revenue - non-current Deferred Revenue, Noncurrent Deferred Revenue, Noncurrent, Total Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Vesting of restricted stock (in shares) IPO [Member] Initial Public Offering External Discovery Related Costs and Other External discovery related costs and other. External - discovery related costs and other Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Restricted stock awards, and other stock-based award vesting maximum term Depreciation, Depletion and Amortization, Nonproduction Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization expense Depreciation and amortization Disaggregation of Income Statement Expense, Caption, Reimbursement from Another Entity, Amount Amount reimbursed to company Maximum [Member] Maximum Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure, Total Liabilities: Schedule of Stock by Class [Table Text Block] Schedule of Preferred Stock by Class Statistical Measurement [Axis] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price Per Unit, Exercised (in dollars per share) Common Stock, Value, Issued Common stock, par value $0.001; 500,000,000 and 200,456,735 shares authorized as of June 30, 2026 and December 31, 2025 respectively; 128,269,428 and 33,116,957 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Warrant Liability Warrant Liability Disclosures [Text Block] The entire disclosure for warrant liability. Finance Lease, Principal Payments Payments on finance lease obligations Development and commercialization expenses Development And Commercialization Expenses Development and commercialization expenses. Principles of Consolidation Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents [Line Items] Shares Reserved For Future Issuance Under The 2019 Plan [Member] Shares reserved for future issuance under the 2019 plan member. Shares Reserved for Future Issuance Under the 2019 Plan Adjustments to additional paid in capital, reclassification of warrant liability to equity upon initial public offering. Reclassification of warrant liability to equity upon initial public offering Adjustments to Additional Paid in Capital, Reclassification of Warrant Liability to Equity Upon Initial Public Offering External General and administrative External general and administrative. External - General and administrative Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Preferred Stock, Shares Authorized Preferred stock share authorized Preferred stock, shares authorized Leasehold Equipment [Member] Leasehold equipment. Leased Equipment Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to non-controlling interest Comprehensive loss attributable to non-controlling interest Conversion of convertible preferred stock to common stock Conversion of Convertible Preferred Stock to Common Stock Conversion of convertible preferred stock to common stock. Related Party Transaction [Line Items] Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Total Entity Registrant Name Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Securities with gross unrealized losses Gross Unrealized Loss Gross Unrealized Loss Series A Convertible Preferred Stock Outstanding [Member] Series a convertible preferred stock outstanding member. Series A Convertible Preferred Stock Outstanding Subsequent Events [Abstract] Consolidated Entities [Domain] Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Provision for income taxes Provision for income tax Shares Issued Upon Warrant Exercised Shares issued upon warrant exercises. Shares issued upon warrant exercised Measurement Frequency [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of Assumptions Used to Determine the Fair Value of the Warrant Entity Common Stock, Shares Outstanding Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive (loss) income Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Revenue recognized under the Collaboration Agreement Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Assets Total assets Property, Plant and Equipment [Table] Weighted Average Remaining Life (in Years) Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Income Statement [Abstract] Cash, Cash Equivalent, and Marketable Security [Text Block] Cash Equivalents and Marketable Securities Sale of Stock, Number of Shares Issued in Transaction Stock sold in the collaboration Fair Value Measurement Liabilities, Level 1 to Level 2 Transfers, Amount Fair value measurement liabilities, level 1 to level 2 transfers, amount. Fair value measurement liabilities, level 1 to level 2 transfers Common stock available for issuance (shares) Issuance of common stock Issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses (in shares) Temporary Equity, Shares Authorized Convertible Preferred Stock Authorized Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Net loss per share, diluted Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Significant Expense Categories and Amounts Align with Segment-Level Information Reclassification of Warrant Liability to Equity upon Initial Public Offering Reclassification of warrant liability to equity upon initial public offering. Reclassification of warrant liability to equity upon initial public offering Series C Convertible Preferred Stock Outstanding Series C Convertible Preferred Stock Outstanding [Member] Series c convertible preferred stock outstanding member. City Area Code Variable Interest Entity Disclosure [Abstract] Variable interest entity disclosure. Restricted cash and cash equivalents (VIE) Restricted Cash and Cash Equivalent, Current Restricted Cash and Cash Equivalent, Current, Total Finance lease liabilities, net of current portion Finance Lease, Liability, Noncurrent Share Based Payment Performance Condition Aggregate Specified Payment Received Share based payment performance condition aggregate specified payment received. Stock options Issued aggregate specified payments Accrued Research and Development Accrued research and development. Research and development Stock Issued During Period, Value, Employee Stock Purchase Plan Stock options payment Reverse stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Year Remaining transaction price recognized year Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Vesting of restricted stock Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Operating Income (Loss) Loss from operations Retained Earnings [Member] Accumulated Deficit [Member] Cash and Cash Equivalents [Axis] Non-cash stock-based compensation Share-Based Payment Arrangement, Noncash Expense Share-Based Payment Arrangement, Noncash Expense, Total Measurement Input, Price Volatility [Member] Measurement Input, Price Volatility Payments of Stock Issuance Costs Net of issuance costs Vesting of Restricted Stock Vesting of restricted stock. Vesting of restricted stock Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Gross Unrealized Loss Operating Lease, Liability, Noncurrent Operating lease liabilities - non-current Fair Value, Inputs, Level 1 [Member] Class of Stock [Line Items] Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Investments, Fair Value Disclosure Investments, Fair Value Disclosure, Total Marketable securities: Nonoperating Income (Expense) [Abstract] Other income (expense), net Stock Option Valuation [Member] Stock Option Valuation Stock Option Valuation Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share Debt Securities, Available-for-Sale [Table] Entity Interactive Data Current Statement of Income Location, Balance [Domain] Collaboration Agreement Eligible To Receive Potential Milestone Payments Collaboration agreement eligible to receive potential milestone payments. Eligible to receive potential milestone payments Operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Furniture and Fixtures [Member] Furniture and Fixtures Convertible Preferred Stock, Shares Issued upon Conversion Stock issuable upon conversion Shares issued upon conversion Increase (Decrease) in Other Noncurrent Liabilities Other long term liabilities Entity Tax Identification Number Revenue: Revenues [Abstract] Share Price Public offering price # of Holdings Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Related Party Expenses Related party expenses. Related party expenses Marketable Securities Marketable Securities [Member] Marketable securities. Amortized Cost And Fair Value Of Companys Cash Equivalents And Marketable Securities [Table Text Block] Amortized cost and fair value of companys cash equivalents and marketable securities. Summary of Amortized Cost and Fair Value of Company's Cash Equivalents and Marketable Securities Local Phone Number Related Party Transaction [Domain] Other current liabilities Other Liabilities, Current Jason Silvers [Member] Jason Silvers. Jason Silvers Accounting Policies [Abstract] Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenue Class of Stock [Domain] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average recognition period Accrued Professional Fees, Current Legal and professional Cash, Cash Equivalents, and Short-Term Investments Cash, Cash Equivalents, and Short-Term Investments, Total Cash, cash equivalents and marketable securities Affiliated Entity [Member] Pioneering Medicines 02, Inc Stock, Class of Stock [Table] Disaggregation of Income Statement Expense, Caption, Reimbursement to Another Entity, Amount Net reimbursement payable Entity Emerging Growth Company Exercise of Common Stock Warrants Shares Exercise of common stock warrants shares. Exercise of common stock warrants (in shares)